Hereditary transthyretin-mediated amyloidosisNews & Research

3 curated articles for Hereditary transthyretin-mediated amyloidosis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.

ℹ
UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data
  1. Health science reports Mar 6, 2026

    Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin-Mediated Amyloidosis: A Systematic Review.

    Hereditary transthyretin-mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life-threatening conditions like cardiomyopathy and polyneuropathy. For treatment of hATTR in the new medical realm, there is a breakthrough discovery of a medicine called Eplonter...

    Why it matters: Recent peer-reviewed research on Hereditary transthyretin-mediated amyloidosis that may be relevant for patients and caregivers.

  2. Neurology and therapy Mar 4, 2026

    Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A.

    In the phase 3 HELIOS-A study (NCT03759379), vutrisiran significantly improved a range of disease-related endpoints compared with an external placebo in patients with hereditary transthyretin amyloidosis (ATTRv) with polyneuropathy (ATTRv-PN). This post hoc analysis examined the effects of vutrisira...

    Why it matters: Recent peer-reviewed research on Hereditary transthyretin-mediated amyloidosis that may be relevant for patients and caregivers.

  3. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis Feb 18, 2026

    Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis.

    Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis.

    Why it matters: Recent peer-reviewed research on Hereditary transthyretin-mediated amyloidosis that may be relevant for patients and caregivers.

More on Hereditary transthyretin-mediated amyloidosis

Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.